Biotech's Leading the way in Life Altering Cancer Therapies

LAS VEGAS, September 20, 2017 /PRNewswire/ --

Over the course of the last few years we have seen significant gains in life changing cancer therapies. These gains in cancer science are set to continue to be more frequent, and significant. Biotechnology companies that are focused on this incredibly large, and needed market of cancer drugs are going to reap the benefits. According to Zion Market Research the Global cancer market is set to reach $161.30 Billion by 2021. Biotech companies involved in the cancer treatment market, that everyone should take notice of immediately include:Propanc Biopharma, Inc. (OTC: PPCB), Kura Oncology, Inc. (NASDAQ: KURA), NewLink Genetics Corporation (NASDAQ: NLNK), Stemline Therapeutics, Inc. (NASDAQ: STML), and Verastem, Inc. (NASDAQ: VSTM).

Propanc Biopharma, Inc. (OTCQB: PPCB)

Market Cap: $1.45M, Current Share Price: $0.24 

If you've been keeping up with the bio-pharmaceutical world, you already know that Propanc Biopharma, Inc. (PPCB) is navigating a new frontier in cancer therapy treatment. Their FDA Orphan Drug Designated pancreatic cancer therapy, PRP, is an intravenous combination of two pancreatic proenzymes. PRP targets tumors to prevent recurrence and metastasis, which is the main cause of patient death from cancer.

Just recently, PPCB published a press release "Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies." In this press release PPCB's CEO, James Nathanielsz, stated "We are very pleased with the progress of the purification and characterization of the two key active components for PRP, trypsinogen and chymotrypsinogen, and we're now moving into the Good Manufacturing Practice (GMP) phase of the manufacturing process, to ensure the IMP meets the strict guidelines for pharmaceutical use in humans."

The press released information on all activities related to the commencement of their First-In-Human (FIH) study on PRP. They are making significant progress towards the full scale manufacture of the investigational medicinal product (IMP) PRP. The full scale manufacture of PRP is a key step in order to submit the Company's first clinical trial application, expected in early 2018. Additionally, PPCB is preparing the regulatory documentation for a supporting clinical trial application and an Orphan Drug Designation (ODD) application to the FDA for the treatment of ovarian cancer.

Kura Oncology, Inc. (NASDAQ: KURA)

Market Cap: $359.93M, Current Share Price: $13.50 

KURA is a clinical-stage biopharmaceutical company, and like PPCB, focused on treating cancer. They saw its shares double earlier today after the firm announced results from its mid-stage trial in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).

NewLink Genetics Corporation (NASDAQ: NLNK)

Market Cap: $538.32M, current share price: 18.27 

NLNK a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel immuno-oncology product candidates with the aim to improve the lives of patients suffering from cancer. NLNK released updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics' IDO pathway inhibitor, in combination with the PD-1 pathway inhibitor, KEYTRUDA (pembrolizumab) earlier this week.

Stemline Therapeutics, Inc. (NASDAQ: STML)

Market cap: $271.8M, Current Share Price: $10.75 

STML, a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced the presentation of clinical data from the ongoing SL-801 Phase 1 trial in patients with advanced solid tumors. The data was presented at the European Society of Medical Oncology (ESMO) Annual Congress 2017 in Madrid, Spain.

Verastem, Inc. (NASDAQ: VSTM)

Market Cap: $200.129M, Current Share Price: $5.34 

VSTM is a clinical stage biopharmaceutical company also focuses on discovering and developing drugs to improve outcomes for patients with cancer. Verastem, Inc.'s shares exploded on Wednesday (9/6/17) and closed the day up 28.13%. The stock hit a new 52-week high of $5.55 yesterday and traded nearly 21 million shares compared to an average of just about 970,000. This was after announcing the expansion of its duvelisib development program to include peripheral t-cell lymphoma upon receiving fast track designation by the FDA.

Content Provided By: Microcap Speculators

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Website: http://microcapspeculators.com/

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link:http://microcapspeculators.com/disclaimer/  

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact  

E-mail: FN Media Group, LLC - editor@financialnewsmedia.com
Phone- +1(954)345-0611